Three years in the past, Summit Therapeutics (SMMT 1.26%) was a little-known small-cap biotech that few traders with a mean tolerance for threat would have bothered to concentrate to on the time. Nevertheless, the corporate’s shares have skyrocketed by greater than 2,000% since then.
As is usually the case within the biotech business, Summit Therapeutics owes this terrific run to scientific progress from its main pipeline candidate. And even after the numerous positive aspects it has skilled in recent times, it would nonetheless be early sufficient to get on the bandwagon.
Here is what traders must know.
SMMT Complete Return Degree information by YCharts
Taking over a large of the business
Summit Therapeutics’ main candidate, ivonescimab, was initially developed by Akeso Biopharma, a China-based biotech firm. Summit’s licensing settlement with its companion granted the previous the rights to the drugs in most areas, particularly people who drugmakers goal probably the most, the U.S. and Europe, since they are typically probably the most profitable.
Ivonescimab is authorized in China. Summit is working scientific trials for the drugs to earn commercialization rights within the U.S. What makes this investigational drugs revolutionary? In a section 3 examine performed in China, ivonescimab proved simply as efficient — certainly, much more efficient — than Merck‘s Keytruda in lowering the danger of development or demise in sufferers with non-small cell lung most cancers (NSCLC) and a PD-L1 protein overexpression.
Picture supply: Getty Pictures.
Let’s put that achievement in context. In keeping with Summit Therapeutics, it was the primary time any drugs beat out Keytruda in a head-to-head late-stage examine in NSCLC. Keytruda is not simply any most cancers drugs; it’s presently the world’s top-selling drug. And because it so occurs, NSCLC is considered one of its extra necessary markets. Not solely was it considered one of its first indications within the U.S. means again in 2015, however lung most cancers can also be the main reason behind most cancers demise — and 85% of lung most cancers instances are of the NSCLC selection.
Ivonescimab might problem this market chief, which is powerful proof that Summit Therapeutics certainly has a revolutionary drug on its palms that might generate billions in annual gross sales at its peak.
A possible pipeline in a drug
Here is one more reason ivonescimab is so promising, The medication is being investigated as a possible remedy throughout a variety of various cancers. Among the drugs’s targets embody colorectal most cancers, hepatocellular carcinoma (liver most cancers), and extra. Summit’s crown jewel is emulating Keytruda on this means as nicely: It could possibly be a possible pipeline in a drug. Though NSCLC must be its most necessary market, the drugs might additionally earn a slew of label expansions usually, resulting in constant income and earnings progress over a protracted interval.
Some would possibly argue that ivonescimab’s success is already baked into Summit Therapeutics’ inventory value. After the corporate’s spectacular run, is there any upside left? In my opinion, there’s, offered ivonescimab delivers. There may be already a considerable quantity of knowledge on the drugs’s security and efficacy from trials performed in China. Whereas that can’t be used to assist approval within the U.S., it helps remove a few of the threat concerned in investing in clinical-stage biotech corporations whose pipeline candidates have by no means been authorized by any regulatory authorities wherever.
Summit Therapeutics just isn’t your common, younger biotech that generates no income and constantly operates at a loss. Even with that, there’s nonetheless some threat that Summit’s promising drug will ultimately encounter scientific or regulatory setbacks — one thing even seasoned drugmakers expertise. Additional, competitors is heating up within the bispecific antibody (the category of medication ivonescimab belongs to) market, with a number of main pharmaceutical corporations, together with Merck, dipping their toes on this area.
It is important to think about these potential challenges, however Summit Therapeutics’ shares stay enticing as a consequence of ivonescimab’s excellent potential. Initiating a place within the firm’s shares at the moment might result in monster returns over the long term.
